skip to main content
Ask New Question

Contraindications for hrt ,examples of hrt preparations,difference between hrt

Guideline-aligned answer with reasoning, red flags and references. Clinically reviewed by Dr Kola Tytler MBBS CertHE MBA MSt MRCGP.

Posted: 1 October 2026Updated: 1 October 2026 Guideline-Aligned (High Confidence) Clinically Reviewed

Contraindications and precautions

  • The supplied extracts do not provide a complete list of systemic HRT contraindications; they identify pregnancy, jaundice or deterioration in liver function, a significant increase in blood pressure, and new-onset migraine-type headache as reasons to discontinue treatment .
  • Dydrogesterone is contraindicated with current or previous meningioma .
  • Conditions requiring close supervision—not presented as automatic contraindications in these extracts—include fibroids/endometriosis, thromboembolic risk factors, a family history of breast cancer, hypertension, liver disorders, diabetes, gallstones, migraine, SLE, previous endometrial hyperplasia, epilepsy, asthma and otosclerosis .
  • Seek specialist menopause advice where contraindications exist, a condition may be affected by HRT, or the appropriate treatment is uncertain .

Examples of HRT preparations

  • Systemic combined HRT: oestrogen with a progestogen such as micronised progesterone, dydrogesterone, norethisterone or medroxyprogesterone; combined patches contain norethisterone or levonorgestrel .
  • Separate components: oestrogen with oral micronised progesterone, for example 200 mg/day for 12 days each month in a low-dose sequential regimen, or oestrogen with a 52 mg levonorgestrel intrauterine system for endometrial protection .
  • Local vaginal oestrogen: estradiol tablets such as Vagifem, an estradiol ring such as Estring, or estriol cream such as Ovestin .
  • People with a uterus require a progestogen alongside systemic oestrogen to minimise endometrial hyperplasia and cancer risk .

HRT versus DMPA

The context describes HRT as treatment for menopause-associated symptoms and identifies oral medroxyprogesterone acetate as an HRT progestogen option—10 mg/day for 12 days each month in a low-dose sequential regimen, or a minimum of 2.5 mg/day in a continuous combined regimen . The extracts do not describe depot medroxyprogesterone acetate, so they do not support a comparison of DMPA’s indication, contraceptive action, dosing or mechanism with HRT .

Why amenorrhoea can occur with HRT

  • Continuous combined HRT: oestrogen and progestogen are taken daily, and amenorrhoea is expected by six months after initiation; this regimen is usually recommended after at least 12 months of amenorrhoea before starting HRT .
  • Sequential/cyclical HRT: absence of bleeding reflects an atrophic endometrium .
  • If bleeding is absent on a cyclical regimen, exclude pregnancy in perimenopausal women or those with premature ovarian insufficiency, and check adherence if the progestogen is taken separately .

Educational content only. Always verify information and use clinical judgement.

Continue exploring

Explore these topics in the iatroX reference and learning libraries.